This suggests that passive immunization with tau antibodies is a feasible therapeutic concentrate on and which the CSF degree of p-tau262/356 or on the microtubule binding domain (MTBD) can serve as a helpful biomarker of tau pathology to monitor tau therapeutics in scientific trials.Several colleagues have produced the counterargument the sensor m